Invenio Imaging
Invenio Imaging is a privately held medical device company that sells the FDA-registered, CE-marked NIO Laser Imaging System, which uses Stimulated Raman Histology and deep-learning AI to deliver intraoperative fresh-tissue images in under three minutes for hospitals and surgical centers.
- Company typePrivate
- Founded2012
- HeadquartersMenlo Park, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Invenio Imaging does
Invenio Imaging, Inc. is a privately held medical device company founded in 2012 and headquartered in Santa Clara, California. It develops and commercializes the FDA-registered and CE-marked NIO Laser Imaging System, which applies Stimulated Raman Histology (SRH) — a label-free, coherent-Raman-scattering imaging technique originally discovered at Harvard — to generate histology-quality microscopic images of fresh tissue in under three minutes, without traditional staining or sectioning. The system is paired with the NIO Slide sample-preparation consumable and a vendor-neutral DICOM interface integrated with Ambra Health for image archiving and sharing, and it targets intraoperative use across neurosurgery, interventional pulmonology, urology, ENT, breast oncology, GI endoscopy, and organ transplantation.
The company sells the NIO platform through direct enterprise field sales to hospitals and academic medical centers in the US and EU, with pricing on a quote-based, multi-year contract model. Its revenue mix combines hardware sales of the NIO Laser Imaging System with one-time licenses for AI-based image-analysis modules, including NIO Glioma Reveal — the first CE-marked clinical deep-learning algorithm for intraoperative cancer infiltration detection in diffuse glioma (research-use-only in the US) — and an AI-based Image Analysis Module for lung cancer currently in a US pivotal study with FDA Breakthrough Device Designation. Key commercial partners include Ambra Health (cloud imaging integration), Johnson & Johnson's Lung Cancer Initiative (clinical research), and NVIDIA (compute infrastructure); key reference customers include NYU Langone Health and the University of Freiburg. In January 2026, the company expanded its board with an independent director and representatives from Oak BioCapital and Michigan Biomedical Venture Fund.
Invenio Imaging firmographics
Firmographics- Name
- Invenio Imaging
- Legal name
- Invenio Imaging, Inc.
- Website
- https://invenio-imaging.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Invenio Imaging is a privately held medical device company that sells the FDA-registered, CE-marked NIO Laser Imaging System, which uses Stimulated Raman Histology and deep-learning AI to deliver intraoperative fresh-tissue images in under three minutes for hospitals and surgical centers.
- Ownership category
- akta.pro rank
Invenio Imaging industry classification
Industry- Product category
- Intraoperative Medical Imaging Systems
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Invenio Imaging is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Invenio Imaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- NIO Laser Imaging System (Hardware): Sale of the FDA-registered and CE-marked NIO Laser Imaging System to hospitals and surgical centers for intraoperative tissue imaging.
- AI Software Products: AI-based image analysis modules including NIO Glioma Reveal (CE-marked for EU) and lung cancer detection AI currently in US pivotal study. Revenue from AI software licenses integrated with the hardware system.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise medical device pricing - quote-based |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Invenio Imaging product offering
Product offeringCore offering
Invenio Imaging develops and sells the NIO Laser Imaging System, an FDA-registered and CE-marked medical device that uses proprietary Stimulated Raman Histology (SRH) to produce high-quality microscopic images of fresh, unprocessed tissue in under three minutes during surgery. The company also offers AI-based image analysis modules, including NIO Glioma Reveal (CE-marked for intraoperative brain tumor detection) and a lung cancer biopsy AI module (FDA Breakthrough Device Designation), sold to hospitals and surgical centers.
Product overview
Invenio Imaging offers a platform centered on the FDA-registered and CE-marked NIO Laser Imaging System, which employs proprietary Stimulated Raman Histology (SRH) technology for near real-time intraoperative fresh tissue imaging. The system delivers high-quality microscopic images in under 3 minutes without traditional staining or sectioning. AI-powered analysis modules, including NIO Glioma Reveal (CE-marked for brain cancer detection) and an AI-based Image Analysis Module for lung cancer (FDA Breakthrough Device Designation), add deep learning-based diagnostic capabilities to the core imaging platform. The NIO Slide enables streamlined sample preparation, and all products integrate via vendor-neutral DICOM interface.
Differentiator
Problem solved
Functional benefit
Products and services
- NIO Laser Imaging System FDA-registered and CE-marked laser imaging system that uses Stimulated Raman Histology (SRH) to generate high-quality microscopic images of fresh tissue in 3 minutes or less, enabling near real-time intraoperative diagnosis without staining or sectioning; sold to hospitals and surgical centers for neurosurgery, interventional pulmonology, urology, ENT, breast oncology, GI endoscopy and organ transplantation.
- NIO Glioma Reveal AI-based deep learning image analysis algorithm that identifies areas of cancer infiltration in diffuse glioma patients during neurosurgery; CE-marked for clinical use in the EU and available for research use only in the US.
- AI-based Image Analysis Module for Lung Cancer AI-powered image analysis module designed to assist physicians in evaluating bronchoscopic lung biopsies; in US pivotal study with FDA Breakthrough Device Designation granted.
- NIO Slide Sample preparation product that enables tissue imaging without staining or sectioning by existing OR staff and renders the tissue reusable for downstream molecular and pathology analysis after imaging.
Quantifiable outcome
- Histology in under 3 minutes vs traditional 20-30 minute frozen section process
- +2 more outcomes
Companies that use Invenio Imaging
Customer profileNamed customers3 records
Segments7 records
Ideal customer profiles3 records
Invenio Imaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature5 records
Invenio Imaging partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Adrian WhitfordminorAppointed as Independent Board Director, bringing commercialization expertise in oncology, digital health, and medtech.
- NVIDIAcoreFeatured in NVIDIA Blog post 'The Fastest Path: Healthcare Startup Uses AI to Analyze Cancer Cells in the Operating Room.' NVIDIA provides GPU technology supporting Invenio's near real-time AI processing capabilities for cancer cell analysis.
- Lung Cancer Initiative at Johnson & JohnsoncoreClinical research collaboration agreement focused on advancing lung cancer detection and diagnosis using Invenio's SRH technology and AI-based image analysis. This partnership leverages Johnson & Johnson's resources in oncology to accelerate clinical validation and adoption.
- Ambra HealthcorePartnership to provide pathologists instant access to medical imaging. The Ambra Health cloud-based medical image management platform integrates with Invenio's NIO Laser Imaging System, enabling seamless sharing and archiving of digital pathology images within existing hospital IT infrastructure via DICOM interface.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Invenio Imaging competitors and assessment
Company assessmentBroad incumbents
- Carl Zeiss Meditec: Global leader in surgical and intraoperative microscopy, particularly for ophthalmology and neurosurgery. Highly comparable as a surgical microscopy/imaging incumbent whose installed base and clinical workflows compete with and complement the NIO system.
- Leica Microsystems (Danaher): Major provider of research and surgical microscopy systems and digital pathology platforms. Directly comparable as the incumbent in high-end optical microscopy used in surgical pathology workflows.
- Olympus: Broad surgical and endoscopic imaging incumbent with deep hospital sales channels. Comparable as the dominant OR/endoscopy imaging platform against which Invenio must position its intraoperative imaging value proposition.
- Stryker: Major surgical and OR equipment manufacturer with imaging and navigation offerings across multiple specialties. Comparable as a broad incumbent with the resources and channel to acquire or compete with Invenio in intraoperative imaging.
Direct peers
- Brainlab: Surgical navigation and intraoperative imaging software company focused on neurosurgery and oncology. Directly comparable as a specialized intraoperative imaging/navigation vendor serving the same neurosurgery customers with adjacent workflows.
- Paige.AI: AI-powered digital pathology company with FDA-cleared cancer detection algorithms. Directly comparable as a pathology AI peer; both target AI-based cancer detection but Paige focuses on digital slides rather than fresh tissue.
- Ibex Medical Analytics: AI-based cancer diagnostics platform for pathology. Directly comparable as a competitor in AI-driven tissue-based cancer detection, though Ibex focuses on routine diagnostic pathology rather than intraoperative use.
- PathAI: AI pathology company developing deep learning models for cancer diagnosis. Directly comparable as an AI-pathology peer; both compete for clinician mindshare and reimbursement in AI-assisted tissue diagnosis.
Emerging players
- Proscia: Digital pathology platform with AI applications for oncology. Comparable as an emerging pathology-AI peer whose software approach overlaps with the AI layer of the NIO system.
- Hyperfine: Portable intraoperative MRI company targeting point-of-care imaging. Comparable as an emerging intraoperative imaging peer taking a different modality approach but addressing the same clinical need for real-time surgical imaging.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Invenio Imaging social profiles
Digital presenceInvenio Imaging compliance and trust
Trust signalCompliance4 records
Invenio Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invenio Imaging leadership team
Management profileNumber of profiles
Profiles8 records
Invenio Imaging funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invenio Imaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invenio Imaging
What does Invenio Imaging do?
Invenio Imaging develops and sells the NIO Laser Imaging System, an FDA-registered and CE-marked medical device that uses proprietary Stimulated Raman Histology (SRH) to produce high-quality microscopic images of fresh, unprocessed tissue in under three minutes during surgery. The company also offers AI-based image analysis modules, including NIO Glioma Reveal (CE-marked for intraoperative brain tumor detection) and a lung cancer biopsy AI module (FDA Breakthrough Device Designation), sold to hospitals and surgical centers.
Is Invenio Imaging a public or private company?
Invenio Imaging is a private company. It is classified as venture growth investor backed and is currently operating.
When was Invenio Imaging founded?
Invenio Imaging was founded in 2012. It employs 1 to 10 people.
Where is Invenio Imaging based?
Invenio Imaging is headquartered in Menlo Park, United States, in the North America region.
How does Invenio Imaging make money?
Two revenue lines are on record. NIO Laser Imaging System (Hardware) is the primary driver. The others are AI Software Products.
Who are Invenio Imaging's main competitors?
Broad incumbents on record are Carl Zeiss Meditec, Leica Microsystems (Danaher), Olympus and Stryker. Direct peers are Brainlab, Paige.AI, Ibex Medical Analytics and PathAI. Emerging players are Proscia and Hyperfine.
Does Invenio Imaging have an API?
No public API is recorded for Invenio Imaging.
What industry is Invenio Imaging in?
Invenio Imaging's product category is Intraoperative Medical Imaging Systems. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339112 and its SIC code is 3841.